Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development.

ABSTRACT:

Introduction

The incidence of type 1 diabetes (T1D) is increasing worldwide and there is a very large need for effective therapies. Essentially no therapies other than insulin are currently approved for the treatment of T1D. Drugs already in use for type 2 diabetes and many new drugs are under clinical development for T1D, including compounds with both established and new mechanisms of action. Content of the Review: Most of the new compounds in clinical development are currently in Phase 1 and 2. Drug classes discussed in this review include new insulins, SGLT inhibitors, GLP-1 agonists, immunomodulatory drugs including autoantigens and anti-cytokines, agents that regenerate β-cells and others. Regulatory Considerations: In addition, considerations are provided with regard to the r

SUBMITTER: Mittermayer F 

PROVIDER: S-EPMC5748875 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature